The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Pegylated interferon and ribavirin therapy non-responders are the focus of a Phase 4 study evaluating the safety and efficacy of Infergen® (consensus interferon) in combination with ribavirin.
Continue reading »A Brazilian case study report indicates that by adding thalidomide to standard combination therapy, six HCV-positive, prior non-responders experienced total remission of their chronic Hepatitis C. Known to cause severe congenital abnormalities, thalidomide's safety and efficacy must be investigated in future Hepatitis C trials before being considered as a viable treatment.
Continue reading »DNA vaccines are the next wave of hope in disease prevention. Scheduled to make its clinical trial debut in early 2007, Inovio's proprietary electroporation DNA delivery system is designed to activate a T-cell response capable of clearing HCV.
Continue reading »An Australian clinical trial is testing a novel strategy for battling Hepatitis C. Physicians are starting to treat Hepatitis C patients with oglufanide, a drug capable of regulating the body's immune response.
Continue reading »Spanish researchers recently investigated the growing trend of basing ribavirin dosages on weight for those co-infected with HIV and Hepatitis C. Their results demonstrate substantial benefit to weight-dosing, and confirm the need for this individualized treatment approach.
Continue reading »Designed to have more anti-viral and immune-stimulating activity, Maxy-alpha is Roche's next generation interferon alpha for Hepatitis C treatment. Roche has initiated a Phase 1a study to determine the safety and efficacy of this drug.
Continue reading »When two separate studies produce identical results, medical innovations quickly follow. Researchers from Scripps Institute and La Jolla Institute for Allergy and Immunology have come to the same conclusion: Altering a specific immune system molecule allows a rat to successfully fight Hepatitis C. If these findings can be reproduced in humans, an entirely new way to eradicate Hepatitis C may be on the horizon.
Continue reading »Currently in a Phase 2b clinical trial to evaluate its efficacy, safety and quality of life effects, HCV participants on AlbuferonTM with Ribavirin are showing positive results. Compared to one of the most popular treatment options available, interim trial results after 12 weeks show more favorable life markers with this new drug combination.
Continue reading »Granted fast track status, Roche's® R1626 is beginning a Phase II study to evaluate its safety and HCV anti-viral activity. Administered in combination with PEGASYS® and COPEGUS®, this trial is now enrolling people with HCV genotype 1 who have previously not received treatment.
Continue reading »Nearly 1,300 people with Hepatitis C genotype 1, the most common strain in the US, will be testing a new drug in a Phase III trial. The new drug, Albuferon, will be compared with the current gold standards of HCV treatment, PEGASYS® and PEG-IFN alpha 2a.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
